Precision Medicine

A new health tech firm says its unified platform can fix patient confusion and provider burnout. But in a crowded market, can one company truly solve it all?

Global marketing giant Dentsu partners with BranchLab, using AI to target health audiences with unprecedented precision while upholding patient privacy.

Australian biotech Amplia Therapeutics is bringing its promising pancreatic cancer trial to the US, a key step in developing a drug that targets the disease's defenses.

Bio-Techne promotes Steve Crouse to lead its high-growth Diagnostics and Spatial Biology unit, signaling a strategic focus on innovation after a key divestiture.

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

Insight Molecular Diagnostics secures $26M to expand its transplant rejection test to the heart market, backed by a major shareholder amid market dilution concerns.

SOFIE Biosciences' FAPI-PRO trial begins, testing a novel radiotracer that could revolutionize the detection of one of the deadliest forms of cancer.

Pharma veteran Pinder Sahota joins digital health firm Reset Health, signaling a strategic shift to integrated care in the new era of weight-loss drugs.

Zelluna partners with Medpace for a first-in-human trial of its ZIMA-101 TCR-NK therapy, a new 'off-the-shelf' approach for hard-to-treat solid tumors.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

Bolstered by a top regulatory expert and unique veterinary data, Vivos Inc. is set to file for human trials of its precision injectable cancer treatment.

Enanta Pharmaceuticals unveils promising data for EDP-978, an oral drug targeting the root cause of conditions like chronic hives, asthma, and eczema.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

From its unique seat at the World Government Summit, CanSinoBIO unveils its next-gen vaccine pipeline and global strategy to fight humanity's oldest diseases.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

Heart disease is the leading cause of premature death for Canadian women, yet it remains under-diagnosed and under-treated. A national movement is fighting back.

Global giant CSL taps Swiss biotech Memo Therapeutics in a landmark deal, signaling a major shift from plasma to lab-grown immunotherapies.